drugset / Trial / NCT06202625
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
Phase 2/3
Recruiting
142 enrolled
Peking University People's Hospital
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · collabFirst Affiliated Hospital of Harbin Medical University · collabFirst Affiliated Hospital of Xinjiang Medical University · collabShanxi Bethune Hospital · collabSichuan Provincial People's Hospital · collabTang-Du Hospital · collabThe First Affiliated Hospital of Nanchang University · collabThe First Affiliated Hospital of Zhengzhou University · collabXiangya Hospital of Central South University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In this study, investigators aim to evaluate the efficacy of avatrombopag in thrombocytopenic patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through a prospective, multi-center, double-blinded, randomized placebo-controlled clinical trial.
Timeline
- Start
- 2024-05-13
- Primary completion
- 2024-10-30
- Completion
- 2025-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 20 mg | Oral |